Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab

Author:

de Vries Tessa1ORCID,Rubio‐Beltrán Eloísa1,van den Bogaerdt Antoon2,Dammers Ruben3,Danser A. H. Jan1ORCID,Snellman Josefin4,Bussiere Jeanine5,MaassenVanDenBrink Antoinette1

Affiliation:

1. Division of Vascular Medicine and Pharmacology, Department of Internal Medicine Erasmus University Medical Center Rotterdam The Netherlands

2. Heart Valve Department ETB‐BISLIFE Beverwijk The Netherlands

3. Department of Neurosurgery Erasmus University Medical Center The Netherlands

4. Novartis Pharma AG Basel Switzerland

5. Amgen Inc Thousand Oaks California USA

Abstract

AbstractBackground and PurposeMultiple drugs targeting the calcitonin gene‐related peptide (CGRP) receptor have been developed for migraine treatment. Here, the effect of the monoclonal antibody erenumab on CGRP‐induced vasorelaxation was investigated in human isolated blood vessels, as well as the effect of combining erenumab with the small molecule drugs, namely rimegepant, olcegepant, or sumatriptan.Experimental ApproachConcentration–response curves to CGRP, adrenomedullin or pramlintide were constructed in human coronary artery (HCA) and human middle meningeal artery (HMMA) segments, incubated with or without erenumab and/or olcegepant. pA2 or pKb values were calculated to determine the potency of erenumab in both tissues. To study whether acutely acting antimigraine drugs exerted additional CGRP‐blocking effects on top of erenumab, HCA segments were incubated with a maximally effective concentration of erenumab (3 μM), precontracted with KCl and exposed to CGRP, followed by rimegepant, olcegepant, or sumatriptan in increasing concentrations.Key ResultsErenumab shifted the concentration‐response curve to CGRP in both vascular tissues. However, in HCA, the Schild plot slope was significantly smaller than unity, whereas this was not the case in HMMA, indicating different CGRP receptor mechanisms in these tissues. In HCA, rimegepant, olcegepant and sumatriptan exerted additional effects on CGRP on top of a maximal effect of erenumab.Conclusions and ImplicationsGepants have additional effects on top of erenumab for CGRP‐induced relaxation and could be effective in treating migraine attacks in patients already using erenumab as prophylaxis.

Funder

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Publisher

Wiley

Reference67 articles.

1. AbbVie Inc. (2021).FDA Approves QULIPTA™ (atogepant) the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine. InPR Newswire.https://www.prnewswire.com/news-releases/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine-301387297.html

2. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

3. Allergan plc. (2019).Allergan receives U.S. FDA approval for UBRELVY™ for the acute treatment of migraine with or without aura in adults.https://www.prnewswire.com/news-releases/allergan-receives-us-fda-approval-for-ubrelvy-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults-300979082.html: PR Newswire.

4. Amgen Inc. (2021).AIMOVIG (erenumab‐aooe) prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761077s009lbl.pdf

5. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3